Merge eMed to Unveil Newest Imaging Workflow Solutions at Radiology Conference

MILWAUKEE, Nov. 14 /PRNewswire-FirstCall/ — Merge eMed, a Merge Healthcare company, (Nasdaq: MRGE; TSX: MRG), today announced that it will unveil its newest technology solutions at the Radiological Society of North America (RSNA), November 26 through 30 at McCormick Place in Chicago, IL. Merge eMed will exhibit in Booth #4707 in the South Building-Hall A. Merge eMed will show software that is relevant to increasing productivity and driving new referrals for imaging businesses. Thousands of hospitals, imaging centers and specialty clinics use solutions from Merge eMed, and many of these customers have played an important role in guiding the company with its newest offerings, including:


Merge eMed will show its premier new solution, Fusion RIS/PACS MX*. This imaging informatics offering moves beyond the simple integration of RIS and PACS applications, delivering a single system that is relevant to the entire spectrum of imaging business needs. From a single screen, its “Radiologist Command Center” provides easy point-and-click access to all patient-related information and images, thus eliminating delays and frustrations from toggling and interfacing between disparate applications. Traditional RIS-based information, such as operating performance, insurance, or referral, is now readily accessible within this single solution. Fusion RIS/PACS MX also incorporates embedded document management, Web-enabled distribution, billing and practice analytics capabilities, as well as workflow tools, such as embedded dictation, interrupt sessions, instant messaging, hanging protocols, and more — all available with a minimum of clicks.

Fusion PACS MX(TM)

Merge eMed will showcase its industry-leading 64-bit capabilities* in Fusion PACS MX (formerly Matrix PACS(TM)), which enables extremely fast simultaneous loading of thousands of images. Other new capabilities to be unveiled for its Fusion PACS MX system will include: a) integrated mammography*, which makes digital mammography completely native to the PACS; b) expanded Practice Analysis(TM) features*, which offer new opportunities for data mining, reporting and real-time monitoring of information within the Fusion PACS MX and c) an enhanced archive framework* with capabilities to speed processing, reconcile demographic data inconsistencies, store data from outside radiology, and provide proactive alerts when problems arise or workflow is impeded.

Fusion RIS MX(TM)

Merge eMed will also highlight its Fusion RIS MX solution, which is now used in more than 150 organizations. The Fusion RIS solution has become the cornerstone of many imaging businesses, as it provides a workflow solution that accelerates productivity from scheduling through billing. Merge eMed’s customers are partners in the ongoing innovation of Fusion RIS MX, as RSNA attendees can see in the recently-released Call Center Scheduler Module and capabilities for real-time dashboard analytics.

  Clinical Applications
Several specialty clinical applications will be demonstrated, including:

MergeMammo(TM) (formerly I-Read Mammo) – A multi-modality, vendor-neutral digital mammography workstation, MergeMammo allows organizations to display images simultaneously from different mammography systems and to read all breast imaging studies from a single station, including images from the newly FDA-approved CR for mammography which has been created by medical equipment manufacturers. Works-in-progress being shown for the first time at RSNA include: Improved full-resolution viewing, algorithm-driven display capabilities to optimize screen real estate, and improved inverted imaging.

MergePET/CT(TM) – a vendor-neutral software application designed to optimize digital reading for PET/CT studies using advanced imaging capabilities combined with fast and efficient workflow for PET/CT reporting.

MergeOrtho(TM) – combining image manipulation and automation within an architecture designed for integration and customization, MergeOrtho(TM) offers a comprehensive digital solution for joint arthroplasty, trauma, deformity correction and more. MergeOrtho(TM) supports surgical planning, templating, archiving and distribution.

According to Kenneth Rardin, President and CEO of Merge Healthcare, “Radiology organizations face significant challenges today, especially as they move to next-generation filmless environments that require more tightly integrated RIS, PACS and clinical applications. Merge Healthcare is committed not only to developing excellent technology, but also to helping healthcare organizations more fully understand how to leverage technology to streamline workflow, to optimize efficiency and to maximize productivity.”

  To schedule a demo, visit

*Work In Progress.

Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers’ productivity and enhance the quality of patient care they provide. For additional information, visit our website at

(Logo: )

Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; risks associated with the Company’s possible delisting from the Nasdaq Global Market; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.